{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-083955","form_type":"8-K","ticker":null,"cik":"0001773427","company_name":"SpringWorks Therapeutics, Inc.","filed_at":"2024-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.479669+00:00","generated_at":"2026-05-31T15:22:06.491263+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"SpringWorks appoints Martin Mackay to Board of Directors effective July 29, 2024","bullets":["Mr. Mackay is independent under Nasdaq standards and serves as a Class II director until 2027 annual meeting.","Initial grants: options for 29,445 shares at $36.80 exercise price; RSUs for 9,963 shares.","Mackay brings 30+ years pharma/biotech R&D experience from Pfizer, AstraZeneca, and Alexion.","Compensation follows company's non-employee director policy; standard indemnification agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-083955","json":"https://secwatch.observer/filing/0001104659-24-083955.json","markdown":"https://secwatch.observer/filing/0001104659-24-083955.md","text":"https://secwatch.observer/filing/0001104659-24-083955.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1773427/000110465924083955/0001104659-24-083955-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1773427/000110465924083955/tm2420401d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T15:22:06.491263+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e4071a991d","claim":"Martin Mackay was appointed as Director at SpringWorks Therapeutics, Inc..","evidence_excerpt":"On July 26, 2024, the Board of Directors (the “Board”) of SpringWorks Therapeutics, Inc. (the “Company”), appointed Martin Mackay as a member of the Board, effective July 29, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1773427/000110465924083955/0001104659-24-083955-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}